Telik (TELK) says it's completed its End of Phase 2 meeting with the FDA for its MDS treatment Telintra, with a preliminary agreement reached regarding the design of a Phase 3 trials.
Hopefully Telintra arm doesn't cause quicker death than the control arm. What a miserable history TELK has had.